Pedro Clavero-Ibarra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5685330/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mediterranean diet improves cognition: the PREDIMED-NAVARRA randomised trial. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1318-1325.	0.9	534
2	Virgin olive oil supplementation and long-term cognition: the Predimed-Navarra randomized, trial. Journal of Nutrition, Health and Aging, 2013, 17, 544-552.	1.5	216
3	Grey matter hypometabolism and atrophy in Parkinson's disease with cognitive impairment: a two-step process. Brain, 2014, 137, 2356-2367.	3.7	119
4	Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1767-1777.	3.3	97
5	Homocysteine and cognitive impairment in Parkinson's disease: A biochemical, neuroimaging, and genetic study. Movement Disorders, 2009, 24, 1437-1444.	2.2	82
6	Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort. Parkinsonism and Related Disorders, 2019, 66, 151-157.	1.1	71
7	Beta activity in the subthalamic nucleus during sleep in patients with Parkinson's disease. Movement Disorders, 2009, 24, 254-260.	2.2	54
8	Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson's disease patients with mild cognitive impairment. Human Brain Mapping, 2016, 37, 968-977.	1.9	40
9	Nonâ€motor symptom burden is strongly correlated to motor complications in patients with Parkinson's disease. European Journal of Neurology, 2020, 27, 1210-1223.	1.7	40
10	Longitudinal Assessment of the Pattern of Cognitive Decline in Non-Demented Patients with Advanced Parkinson's Disease. Journal of Parkinson's Disease, 2014, 4, 677-686.	1.5	32
11	<pre><scp>COPPADIS</scp>â€2015 (<scp>CO</scp>hort of Patients with PArkinson's <scp>DI</scp>sease in) Tj ETQ 1000 subjects included. Results from the baseline evaluation. European Journal of Neurology, 2019, 26, 1399 1407</pre>	0q1 1 0.78 1.7	34314 rgBT 0 32
12	The impact of silent vascular brain burden in cognitive impairment in Parkinson's disease. European Journal of Neurology, 2012, 19, 1100-1107.	1.7	31
13	Midbrain microglia mediate a specific immunosuppressive response under inflammatory conditions. Journal of Neuroinflammation, 2019, 16, 233.	3.1	31
14	Parkinson's disease with mild cognitive impairment: severe cortical thinning antedates dementia. Brain Imaging and Behavior, 2019, 13, 180-188.	1.1	25
15	Effect of deep brain stimulation of the subthalamic nucleus on non-motor fluctuations in Parkinson's disease: Two-year' follow-up. Parkinsonism and Related Disorders, 2013, 19, 543-547.	1.1	21
16	The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia. Neurobiology of Disease, 2018, 118, 64-75.	2.1	20
17	Predictors of clinically significant quality of life impairment in Parkinson's disease. Npj Parkinson's Disease, 2021, 7, 118.	2.5	17
18	Effects of Motor Symptom Laterality on Clinical Manifestations and Quality of Life in Parkinson's Disease. Journal of Parkinson's Disease, 2020, 10, 1611-1620.	1.5	15

#	Article	IF	CITATIONS
19	The impact of freezing of gait on functional dependency in Parkinson's disease with regard to motor phenotype. Neurological Sciences, 2020, 41, 2883-2892.	0.9	13
20	The Relationship Between Atrophy and Hypometabolism: Is It Regionally Dependent in Dementias?. Current Neurology and Neuroscience Reports, 2015, 15, 44.	2.0	11
21	High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson's disease patients. Journal of Neural Transmission, 2019, 126, 1599-1608.	1.4	11
22	Espacios de Virchow-Robin mesencefálicos y parkinsonismo: caso clÃnico y revisión de la literatura. NeurologÃa, 2021, 36, 171-173.	0.3	2